PAK1 and breast carcinoma: Treatment of PAK1 overexpressing and PAK1-amplified breast cancer cells with each of these drugs had a similar effect, and interestingly, coadministration of both inhibitors caused a very significant reduction (72-78 %) in cell survival (Figure 5B and 5C).